Literature DB >> 32105405

P53 in RhoA regulation.

Nektarios Barabutis1.   

Abstract

Recent evidence suggest that dysregulation of the tumor suppressor P53, in combination with disharmonious activities of the small GTPase RhoA, may lead to irreversible progression of human disease. The purpose of the present study is to communicate the most recent information regarding the highly interrelated P53/RhoA network. Laborious investigations in the association between both components, may reveal new targets for opposing severe human disease, including the acute respiratory distress syndrome.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  acute lung injury; acute respiratory distress syndrome; endothelium; inflammation

Mesh:

Substances:

Year:  2020        PMID: 32105405     DOI: 10.1002/cm.21604

Source DB:  PubMed          Journal:  Cytoskeleton (Hoboken)        ISSN: 1949-3592


  5 in total

1.  Autophagy, Unfolded Protein Response and Lung Disease.

Authors:  Mohammad S Akhter; Mohammad A Uddin; Khadeja-Tul Kubra; Nektarios Barabutis
Journal:  Curr Res Cell Biol       Date:  2020-10-15

2.  Protective effects of GHRH antagonists against hydrogen peroxide-induced lung endothelial barrier disruption.

Authors:  Mohammad S Akhter; Khadeja-Tul Kubra; Nektarios Barabutis
Journal:  Endocrine       Date:  2022-10-20       Impact factor: 3.925

3.  Effects of Heat Shock Protein 90 Inhibition In the Lungs.

Authors:  Mohammad A Uddin; Khadeja-Tul Kubra; Jafrin Jobayer Sonju; Mohammad S Akhter; Jois Seetharama; Nektarios Barabutis
Journal:  Med Drug Discov       Date:  2020-05-17

4.  P53 deficiency potentiates LPS-Induced acute lung injury in vivo.

Authors:  Mohammad A Uddin; Mohammad S Akhter; Khadeja-Tul Kubra; Nektarios Barabutis
Journal:  Curr Res Physiol       Date:  2020-07-09

5.  Elucidation of the Molecular Pathways Involved in the Protective Effects of AUY-922 in LPS-Induced Inflammation in Mouse Lungs.

Authors:  Mohammad S Akhter; Mohammad A Uddin; Khadeja-Tul Kubra; Nektarios Barabutis
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.